Analysis of the diseases and indications that Sunitinib (Sutent) mainly treats

Sunitinib (Sunitinib, trade name Sutent) is an oral small molecule multi-target tyrosine kinase inhibitor that mainly inhibits vascular endothelial growth factor receptor (VEGFR) , platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KIT) and other signaling pathways to achieve anti-tumor effects, prevent tumor angiogenesis and inhibit cancer cell proliferation. Due to its broad mechanism of action, sunitinib is widely used in the treatment of a variety of solid tumors and is clinically important.

Sunitinib is approved as a first-line treatment for renal clear cell carcinoma (RCC). For patients with locally advanced or metastatic clear cell renal cell carcinoma, sunitinib can significantly prolong progression-free survival (PFS) and overall survival (OS), and has become one of the standard regimens in clinical practice. By inhibiting tumor angiogenesis, it effectively slows down tumor growth and provides patients with a valuable therapeutic window.

In gastrointestinal stromal tumors (GIST), sunitinib is usually used in patients who are resistant or intolerant to imatinib (Imatinib). GIST is a type of tumor originating from the stromal cells of the gastrointestinal tract, often accompanied by c-KIT or PDGFRA gene mutations. By targeting these mutated receptors, sunitinib can inhibit the growth and spread of tumor cells, improve patient symptoms and prolong survival. Clinical studies have shown that sunitinib has significant efficacy advantages in such patients.

In addition, sunitinib has also shown certain efficacy in pancreatic neuroendocrine tumors (pNET). For patients with unresectable or progressive pNET, sunitinib can delay tumor growth and improve disease control rate (DCR). In general, sunitinib, as a multi-target tyrosine kinase inhibitor, covers a variety of vascular dependence and receptor mutation-related tumors. Its indications include renal clear cell carcinoma, GIST and pancreatic neuroendocrine tumors, providing an effective treatment option for patients with a variety of malignant tumors.

Reference materials:https://www.drugs.com/